|
Chimeric Antigen Receptor T-Cell Therapy Clinical Trials
6 actively recruiting trials across 5 locations
▼ -1 trial since June 2026
Also known as: Axi-Cel, CAR T Infusion, CAR T Therapy, CAR T-cell Therapy, Chimeric Antigen Receptor T-cell Infusion +1 more
Pipeline
Early 1: 1Phase 1: 1Phase 2: 4
Top Sponsors
- City of Hope Medical Center2
- University of Washington1
- University of California, Davis1
- Mayo Clinic1
- H. Lee Moffitt Cancer Center and Research Institute1
Indications
- Cancer6
- Refractory Diffuse Large B-Cell Lymphoma3
- Recurrent Diffuse Large B-Cell Lymphoma3
- Refractory Primary Mediastinal Large B-Cell Lymphoma2
- Refractory Grade 3b Follicular Lymphoma2
Duarte, California2 trials
Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma
City of Hope Medical Center
Early 1
Scottsdale, Arizona1 trial
Sacramento, California1 trial
Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy
University of California Davis Comprehensive Cancer Center
Phase 2
Tampa, Florida1 trial
Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL
Moffitt Cancer Center
Phase 2
Seattle, Washington1 trial
Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
Fred Hutch/University of Washington Cancer Consortium
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.